Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
Low plasma levels of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) are associated with decreased low-density lipoprotein (LDL) cholesterol and a reduced risk of cardiovascular disease. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of LDL receptors (LDLR), very low-density...
Guardado en:
Autores principales: | Rhogerry Deshycka, Valentino Sudaryo, Nai-Jia Huang, Yushu Xie, Liyan Y. Smeding, Moon Kyung Choi, Hidde L. Ploegh, Harvey F. Lodish, Novalia Pishesha |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6e2cb9ebe8ff46288add6d9019ba5414 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.
por: Rhogerry Deshycka, et al.
Publicado: (2021) -
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
por: Nai-Jia Huang, et al.
Publicado: (2017) -
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Camilla Gustafsen, et al.
Publicado: (2017) -
Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells
por: Allicia Jack, et al.
Publicado: (2021) -
Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering
por: Peng Sun, et al.
Publicado: (2021)